secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLOBUS MEDICAL INC (GMED)
CIK:        0001237831
Form:       8-K
Filed at:   2025-01-08T23:59:59+00:00
Accession:  0001562762-25-000006
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Globus Medical prelim Q4 sales $657M (+6.6% YoY), FY24 $2.52B; guides FY25 rev $2.66-2.69B
--------------------------------------------------------------------------------

- Q4 2024 preliminary net sales ~$657M, up 6.6% as-reported vs Q4 2023; FY2024 ~$2.52B, up 60.6%.
- FY2025 revenue guidance $2.66-2.69B; fully diluted non-GAAP EPS $3.40-$3.50.
- CEO highlights record product launches and highest Enabling Technology placements post-NuVasive merger.
- Full Q4 and FY2024 results to be reported on February 20, 2025 after market close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1237831/000156276225000006/0001562762-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1237831/000156276225000006/gmed-20250108x8k.htm
  HTML page:      https://secwatch.observer/filing/0001562762-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer